An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy

A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease

(2017) Elvira Mass et al.   NATURE

Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas

(2017) E. Ann Yeh et al.   PEDIATRIC BLOOD & CANCER

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

(2016) J.-F. Emile et al.   BLOOD

Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age

(2016) Charlotte Rigaud et al.   BRITISH JOURNAL OF HAEMATOLOGY

Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study

(2016) Akira Morimoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

(2015) J. Donadieu et al.   BLOOD

How I treat Langerhans cell histiocytosis

(2015) C. E. Allen et al.   BLOOD

Treatment of Langerhans cell histiocytosis: it is time to learn from the past

(2015) Milen Minkov et al.   BRITISH JOURNAL OF HAEMATOLOGY

MAP2K1andMAP3K1mutations in langerhans cell histiocytosis

(2015) David S. Nelson et al.   GENES CHROMOSOMES & CANCER

Clinical Characteristics and Treatment of Langerhans Cell Histiocytosis

(2015) Chalinee Monsereenusorn et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease

(2015) Julien Haroche et al.   JOURNAL OF CLINICAL ONCOLOGY

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

(2015) David M. Hyman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis

(2015) Sébastien Héritier et al.   JAMA Oncology

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis

(2014) N. A. Brown et al.   BLOOD

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

(2014) R. Chakraborty et al.   BLOOD

Follow-up of pediatric patients treated by IVIG for Langerhans cell histiocytosis (LCH)-related neurodegenerative CNS disease

(2014) Shinsaku Imashuku et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

(2013) H. Gadner et al.   BLOOD

Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation

(2012) J. Haroche et al.   BLOOD

Langerhans cell histiocytosis: pragmatic empirism on the road to rational cure

(2012) Milen Minkov   EXPERT OPINION ON PHARMACOTHERAPY

Medical management of langerhans cell histiocytosis from diagnosis to treatment

(2012) Jean Donadieu et al.   EXPERT OPINION ON PHARMACOTHERAPY

Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years

(2012) Riccardo Haupt et al.   PEDIATRIC BLOOD & CANCER

Multisystem Langerhans Cell Histiocytosis in Children

(2011) Milen Minkov   PEDIATRIC DRUGS

Recurrent BRAF mutations in Langerhans cell histiocytosis

(2010) G. Badalian-Very et al.   BLOOD

Importance of Multi-lineage Hematologic Involvement and Hypoalbuminemia at Diagnosis in Patients With “Risk-organ” Multi-system Langerhans Cell Histiocytosis

(2010) Jorge Luis Braier et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Central Nervous System Disease in Langerhans Cell Histiocytosis

(2010) Nicole Grois et al.   JOURNAL OF PEDIATRICS

2′-chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the histiocyte society

(2009) Sheila Weitzman et al.   PEDIATRIC BLOOD & CANCER

Nationwide survey of single-system single site Langerhans cell histiocytosis in Japan

(2009) Akira Morimoto et al.   PEDIATRIC BLOOD & CANCER

Neurodegenerative central nervous system Langerhans cell histiocytosis and coincident hydrocephalus treated with vincristine/cytosine arabinoside

(2009) Carl E. Allen et al.   PEDIATRIC BLOOD & CANCER

Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland

(2008) J A Salotti et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry

(2008) Milen Minkov et al.   JOURNAL OF PEDIATRICS

Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004

(2008) Aurélie Guyot-Goubin et al.   PEDIATRIC BLOOD & CANCER

Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients

(2007) Akira Morimoto et al.   PEDIATRIC BLOOD & CANCER

Skeletal Langerhans cell histiocytosis in children: Permanent consequences and health-related quality of life in long-term survivors

(2007) Loretta MS Lau et al.   PEDIATRIC BLOOD & CANCER